ClinicalTrials.gg
Active, not recruitingNCT05608291Updated Nov 10, 2026

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

A Phase 3 interventional study of Fianlimab and Cemiplimab in Melanoma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 211 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,564
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Melanoma by Regeneron Pharmaceuticals — 2 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Regeneron Pharmaceuticals.

Enrollment
Largest of 11
1,564 · median 151
Started
2023
the only one that year
Phase 3
3 of 12
1 open now
Registered
7th of 12
by date

Among the 12 studies in Melanoma by Regeneron Pharmaceuticals, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 3, and was the 7th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 12 studies in Melanoma by Regeneron Pharmaceuticals are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Melanoma by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drugs.
  • How much study drug is in the blood at different times.
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.
  • How administering the study drugs might improve quality of life.
03

Conditions studied

  • Melanoma

Keywords

  • Resected High Risk Melanoma
  • Skin Cancer
  • Stage IIB
  • Stage IIC
  • Stage III
  • Stage IV
  • LAG-3 Lymphocyte activation gene 3
  • Adjuvant Setting
  • anti-PD-1 Monoclonal Antibody
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
  2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
  3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol

Key Exclusion Criteria:

  1. Uveal melanoma
  2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
  3. Ongoing or recent (within 2 years) evidence of disease that required treatment
  4. Uncontrolled infection with (HIV), virus (HBV), or (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
  5. Another that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
  6. Participants with a history of myocarditis
  7. Adolescent patients (≥12 to \<18 years old) with body weight \<40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,564 participants (actual)

Study arms

  • Experimental
    Fianlimab HD + Cemiplimab

    Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab

    Drug: Fianlimab · Drug: Cemiplimab

  • Experimental
    Fianlimab LD + Cemiplimab

    Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab

    Drug: Fianlimab · Drug: Cemiplimab

  • Active comparator
    Pembrolizumab

    Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo

    Drug: Pembrolizumab · Drug: Placebo

Interventions

  • Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

    Also known as: REGN3767

  • Cemiplimab will be administered by IV infusion Q 3 weeks

    Also known as: REGN2810, Libtayo

  • Pembrolizumab will be administered by IV infusion Q 3 weeks

    Also known as: MK-3475, lambrolizumab, Keytruda

  • DrugPlacebo

    Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks

06

What researchers measure

Primary outcomes

  1. Relapse free survival (RSF)

    Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.

    Time frame: Up to 5 Years

Secondary outcomes

  1. Distant metastasis-free survival (DMFS)

    Time between the date of randomization and the date of the first distant metastasis.

    Time frame: Up to 5 Years

  2. Overall survival (OS)

    Time from randomization to the date of death.

    Time frame: Up to 5 Years

  3. Occurrence of treatment-emergent adverse events (TEAEs)

    A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 5 Years

  4. Occurrence of immune-mediated EAEs (im-EAEs)

    imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.

    Time frame: Up to 5 Years

  5. Occurrence of serious adverse events (SAEs)

    An SAE is any untoward medical occurrence that at any dose: * Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger). * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization. * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect. * Is an important medical event

    Time frame: Up to 5 Years

  6. Occurrence of adverse events of special interest (AESIs)

    An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it

    Time frame: Up to 5 Years

  7. Occurrence of TEAEs resulting in death

    A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 5 Years

  8. Occurrence of dose-limiting toxicity (DLT)

    A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.

    Time frame: Up to 5 Years

  9. Occurrence of interruption or discontinuation of study drug(s) due to TEAE

    A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 5 Years

  10. Occurrence of laboratory abnormalities

    As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)

    Time frame: Up to 5 Years

  11. Concentrations of fianlimab in serum over time

    The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

    Time frame: Up to 5 Years

  12. Concentrations of cemiplimab in serum over time

    The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

    Time frame: Up to 5 Years

  13. Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies

    Immunogenicity will be characterized per drug molecule by ADA and NAb status.

    Time frame: Up to 5 Years

  14. Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies

    Immunogenicity will be characterized per drug molecule by ADA and NAb status.

    Time frame: Up to 5 Years

  15. Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)

    The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.

    Time frame: Up to 5 Year

  16. PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L)

    The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: Up to 5 Years

  17. PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma

    The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).

    Time frame: Up to 5 Years

  18. PRO for adults as determined by the Patient Global Impressions Scale (PGIS)

    The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".

    Time frame: Up to 5 Years

  19. PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC)

    The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".

    Time frame: Up to 5 Years

  20. Time to global health status/quality of life deterioration per EORTC QLQ-C30

    Time frame: Up to 5 years

  21. Time to physical functioning deterioration per EORTC QLQ-C30

    Time frame: Up to 5 Years

  22. Time to role functioning deterioration per EORTC QLQ-C30

    Time frame: Up to 5 Years

07

Study locations

211 sites

Showing the first 100 of 211 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 47 months after the start.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's planned 47 months is above that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Nov 8, 2022
StartActual
Jan 16, 2023
Primary completionEst.
Jan 15, 2027was Jul 2026
CompletionEst.
Apr 3, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Sheba Medical Center · Tel HaShomer, Israel
Show 1 removed
  • Sheba Medical Center · Tel Litwinsky, Israel
Nov 10, 2026
Primary completion
Jul 27, 2026→Jan 15, 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    1 site added, 1 site removed
    Show site
    • Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • Sheba Medical Center · Tel Litwinsky, Israel
    Primary completion Jul 27, 2026→Jan 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05608291
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Jan 16, 2023
Primary completion
Jan 15, 2027 (estimated)
Completion
Apr 3, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fianlimab

Start the discussion